https://www.selleckchem.com/pr....oducts/bay-1816032.h
. Using MRI-guided selection for better risk stratification, US without neoadjuvant therapy can be considered in early stage patients with good prognosis. PCRT may not be required for all stage II/III rectal cancer patients, especially for the MRI-proven intermediate-risk group (cT1-2/N1, cT3N without CRM involvement and lateral lymph node metastasis. Further prospective studies are warranted.Brain metastasis, one of the common complications of lung cancer, is an important cause of death in patients with advanced cancer, despite p
Like
Comment
Share
